Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. News
  7. Summary
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Clinuvel Pharmaceuticals : Presentation to Jefferies Healthcare Conference

06/03/2021 | 07:19pm EDT

C O M P A N Y A N N O U N C E M E N T

CLINUVEL Presentation to Jefferies

Healthcare Conference

ASX:

CUV

Melbourne, Australia, 04 June 2021

XETRA-DAX:

UR9

NASDAQ INTERNATIONAL DESIGNATION:

CLVLY

CLINUVEL PHARMACEUTICALS LTD advises its shareholders and interested investors that Chief Executive Officer, Dr Philippe Wolgen presented to the Jefferies Virtual Healthcare Conference at 08:30 (EST) / 22:30 (AEST) on Thursday 03 June 2021.

To view the fireside chat, hosted by Dr David Stanton of Jefferies Australia, please use the following link: https://wsw.com/webcast/jeff174/cuv.au/2086398.

- End -

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global and diversified biopharmaceutical company focused on developing and commercialising treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. As pioneers in photomedicine and understanding the interaction of light and human biology, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair and acute or life- threatening conditions. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014, the US Food and Drug Administration in 2019 and the Australian Therapeutic Goods Administration in 2020 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care. Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore, and the USA. For more information, please go to http://www.clinuvel.com.

SCENESSE® and PRÉNUMBRA® are registered trademarks of CLINUVEL PHARMACEUTICALS LTD.

Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD

Head of Investor Relations

Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD

Investor Enquiries https://www.clinuvel.com/investors/contact-us

Page 1 of 2

CEO Presentation to Jefferies Healthcare Conference

Forward-Looking Statements

This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL's management. Statements may involve a number of known and unknown risks that could cause our future results, performance, or achievements to differ significantly from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialise pharmaceutical products, the COVID-19 pandemic affecting the supply chain for a protracted period of time, including our ability to develop, manufacture, market and sell biopharmaceutical products; competition for our products, especially SCENESSE® (afamelanotide 16mg); our ability to achieve expected safety and efficacy results through our innovative R&D efforts; the effectiveness of our patents and other protections for innovative products, particularly in view of national and regional variations in patent laws; our potential exposure to product liability claims to the extent not covered by insurance; increased government scrutiny in either Australia, the U.S., Europe, China and Japan of our agreements with third parties and suppliers; our exposure to currency fluctuations and restrictions as well as credit risks; the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement; that the Company may incur unexpected delays in the outsourced manufacturing of SCENESSE® which may lead to it being unable to supply its commercial markets and/or clinical trial programs; any failures to comply with any government payment system (i.e. Medicare) reporting and payment obligations; uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology based products; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; any failure to retain or attract key personnel and managerial talent; the impact of broader change within the pharmaceutical industry and related industries; potential changes to tax liabilities or legislation; environmental risks; and other factors that have been discussed in our 2020 Annual Report. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation, outside of those required under applicable laws or relevant listing rules of the Australian Securities Exchange, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. More information on the forecasts and estimates is available on request. Past performance is not an indicator of future performance.

www.clinuvel.com

Level 11

535 Bourke Street

Melbourne

Victoria, Australia, 3000

T +61 3 9660 4900

F +61 3 9660 4999

Page 2 of 2

CEO Presentation to Jefferies Healthcare Conference

Disclaimer

Clinuvel Pharmaceuticals Limited published this content on 04 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 June 2021 23:18:08 UTC.


© Publicnow 2021
All news about CLINUVEL PHARMACEUTICALS LIMITED
03:29aCLINUVEL PHARMACEUTICALS : Books $11 Million Cash Receipts in Fiscal Q4
MT
06/07CLINUVEL PHARMACEUTICALS : Treats First Patient in Phase 2 Study of Stroke Drug;..
MT
06/06CLINUVEL PHARMACEUTICALS : Media release - First stroke patient with afamelanoti..
PU
06/06CLINUVEL PHARMACEUTICALS : First stroke patient treated with afamelanotide
PU
06/06Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with ..
CI
06/03CLINUVEL PHARMACEUTICALS : Presentation to Jefferies Healthcare Conference
PU
06/02CLINUVEL PHARMACEUTICALS : Newsletter 3 - June 2021
PU
04/28CLINUVEL PHARMACEUTICALS : Appendix 4C - quarterly
PU
04/11CLINUVEL PHARMACEUTICALS : Strategic Update II - April 2021
PU
03/31CLINUVEL PHARMACEUTICALS : Newsletter II - April 2021
PU
More news
Financials
Sales 2021 42,1 M 31,1 M 31,1 M
Net income 2021 19,5 M 14,4 M 14,4 M
Net cash 2021 84,3 M 62,3 M 62,3 M
P/E ratio 2021 77,0x
Yield 2021 0,10%
Capitalization 1 468 M 1 087 M 1 085 M
EV / Sales 2021 32,9x
EV / Sales 2022 22,0x
Nbr of Employees -
Free-Float 79,2%
Chart CLINUVEL PHARMACEUTICALS LIMITED
Duration : Period :
Clinuvel Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CLINUVEL PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 29,72 AUD
Average target price 30,64 AUD
Spread / Average Target 3,10%
EPS Revisions
Managers and Directors
Philippe Jacques Wolgen Chief Executive Officer, MD & Director
Darren M. Keamy Chief Financial Officer & Secretary
Willem A. Blijdorp Chairman
Dennis J. Wright Chief Scientific Officer
Lachlan Hay Global Director-Operations
Sector and Competitors
1st jan.Capi. (M$)
CLINUVEL PHARMACEUTICALS LIMITED33.15%1 087
CSL LIMITED2.77%98 032
WUXI BIOLOGICS (CAYMAN) INC.21.21%67 944
SAMSUNG BIOLOGICS CO.,LTD.10.29%52 789
BIOGEN INC.34.43%49 057
ALEXION PHARMACEUTICALS, INC.0.00%40 336